NCR3 and acute lymphoblastic leukemia: There was no significant difference in 2B4, NKp30, and NKp46 expression on CD14+ monocytes in the different risk-stratified groups of ALL patients as compared to healthy individuals either at diagnosis (1BD) or post-induction chemotherapy (2BD) treatment (Figure 4A,B,G–J).